Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.80 |
| ▸ | LCK | P06239 | 3/20 | 0.80 |
| ▸ | LYN | P07948 | 3/20 | 0.80 |
| ▸ | NUDT14 | O95848 | 2/20 | 0.68 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 0.68 |
| ▸ | SRC | P12931 | 2/20 | 0.64 |
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | TEK | Q02763 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 4/20 | 0.61 |
| ▸ | TEC | P42680 | 3/20 | 0.61 |
| ▸ | BMX | P51813 | 3/20 | 0.61 |
| ▸ | TXK | P42681 | 2/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.61 |
| ▸ | ITK | Q08881 | 2/20 | 0.61 |
| ▸ | BLK | P51451 | 2/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.61 |
| ▸ | LATS1 | O95835 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614098 | 1.00 | BTK (0.80) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL1614096 | 1.00 | BTK (0.80) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL17713765 | 1.00 | BTK (0.80) | BTKLCKLYNNUDT14NUDT5 | |
| Hydrochloric Acid SCHEMBL17713741 | 0.99 | BTK (0.78) | BTKLCKLYNNUDT14NUDT5 | |
| Hydrochloric Acid SCHEMBL16931735 | 0.99 | BTK (0.78) | BTKLCKLYNNUDT14NUDT5 | |
| Hydrochloric Acid SCHEMBL16931734 | 0.99 | BTK (0.78) | BTKLCKLYNNUDT14NUDT5 | |
| Hydrochloric Acid SCHEMBL17713743 | 0.99 | BTK (0.78) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL14576054 | 0.94 | BTK (0.76) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL5803386 | 0.94 | BTK (0.76) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL28874582 | 0.93 | BTK (0.70) | BTKLCKLYNNUDT14NUDT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023197914-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | 安徽中科拓苒药物科学研究有限公司 | 2023-10-19 | — | — | WO | claimed |
| CN-114605418-B | Ibrutinib acrylamide derivative with anti-tumor activity, and synthetic method and application thereof | 广东医科大学附属医院 | 2023-09-05 | — | — | CN | claimed |
| CN-115124536-A | Synthesis method of ibrutinib intermediate | 浙江美诺华药物化学有限公司 | 2022-09-30 | — | — | CN | claimed |
| CN-114605418-A | Ibrutinib acrylamide derivative with antitumor activity and synthesis method and application thereof | 广东医科大学附属医院 | 2022-06-10 | — | — | CN | claimed |
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| CN-113929685-B | Preparation method of ibutenib intermediate | 鲁南制药集团股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-113929685-B | Preparation method of ibutenib intermediate | 鲁南制药集团股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240024314-A1 | Methods of Treating Splenomegaly | TELIOS PHARMA, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023197914-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | 安徽中科拓苒药物科学研究有限公司 | 2023-10-19 | — | — | WO | disclosed |
| CN-114605418-B | Ibrutinib acrylamide derivative with anti-tumor activity, and synthetic method and application thereof | 广东医科大学附属医院 | 2023-09-05 | — | — | CN | disclosed |
| CN-113929686-B | Preparation method of ibutenib | 鲁南制药集团股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11642343-B2 | Methods of treating splenomegaly | TELIOS PHARMA, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2023059581-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| US-20220387434-A1 | COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT | QUOGUE IP HOLDINGS LLC (US) | 2022-12-08 | — | — | US | disclosed |
| CN-115124536-A | Synthesis method of ibrutinib intermediate | 浙江美诺华药物化学有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-111004239-B | Preparation method of ibrutinib precursor | 上海柏狮生物科技有限公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-4017843-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2022-06-29 | — | — | EP | disclosed |
| US-20220184069-A1 | METHODS OF TREATING SPLENOMEGALY | TELIOS PHARMA, INC. (US) | 2022-06-16 | — | — | US | disclosed |
| CN-114605418-A | Ibrutinib acrylamide derivative with antitumor activity and synthesis method and application thereof | 广东医科大学附属医院 | 2022-06-10 | — | — | CN | disclosed |
| CN-114502533-A | Benzenesulfonamide derivatives and use thereof | 2692372安大略公司 | 2022-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387434-A1 | COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT | BTK, BCL9L, BCL9 | BTK 1/4885LCK 25/4885LYN 9/4885 |
| US-20250136619-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | CDK9, AURKB, AURKC | BTK 153/4885LCK 60/4885LYN 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.